CN Patent

CN104725350A — 阿格列汀盐酸盐的多晶b型晶体、其制备方法及生产用途

Assigned to HUBEI WATERSTONE BIO-PHARMACEUTICAL TECHNOLOGY Co Ltd · Expires 2015-06-24 · 11y expired

What this patent protects

本发明公开了阿格列汀盐酸盐多晶B型晶体和其制备方法。其中所述多晶B型晶体使用Cu-Kα辐射的X-射线粉末衍射方法,其X射线粉末衍射包含2θ为8.87°±0.2°、12.67°±0.2°、14.39°±0.2°、14.84°±0.2°、16.33°±0.2°、18.66°±0.2°、19.12°±0.2°、20.20°±0.2°、22.49°±0.2°、24.18°±0.2°、24.54°±0.2°、25.48°±0.2°、27.31°±0.2°、28.83°±0.2°、30.18°±0.2°、32.97°±0.2°、36.85°±0.2°、38.76°±…

USPTO Abstract

本发明公开了阿格列汀盐酸盐多晶B型晶体和其制备方法。其中所述多晶B型晶体使用Cu-Kα辐射的X-射线粉末衍射方法,其X射线粉末衍射包含2θ为8.87°±0.2°、12.67°±0.2°、14.39°±0.2°、14.84°±0.2°、16.33°±0.2°、18.66°±0.2°、19.12°±0.2°、20.20°±0.2°、22.49°±0.2°、24.18°±0.2°、24.54°±0.2°、25.48°±0.2°、27.31°±0.2°、28.83°±0.2°、30.18°±0.2°、32.97°±0.2°、36.85°±0.2°、38.76°±0.2°的峰。所得晶体能以高纯度从体系中析出,可以有效的去除反应中的二聚副产物,提高生产效率,降低了生产成本。

Drugs covered by this patent

Patent Metadata

Patent number
CN104725350A
Jurisdiction
CN
Classification
Expires
2015-06-24
Drug substance claim
No
Drug product claim
No
Assignee
HUBEI WATERSTONE BIO-PHARMACEUTICAL TECHNOLOGY Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.